The decision comes after the study failed to demonstrate that the drug reduced COVID symptoms among relatively healthy patients and wasn’t able to show a statistically significant reduction in hospitalization and death. The results mark the latest blow to the company’s ambitions to expand the market for its blockbuster COVID pill. Pfizer said in a statement that the study results aren’t expected to impact its full-year revenue forecast. The drugmaker has already clinched $22 billion in contracts for the COVID pill for 2022. Results from the study of standard-risk COVID patients will be submitted to the Food and Drug Administration as a part of Pfizer’s application for full approval of the product.

Source: Los Angeles Times June 17, 2022 10:22 UTC